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a moderate dose-dependent CYP3A4 inhibitor (Anon, n.a.).
We describe, in this report, the interaction of these twomedications
and how that interaction precipitated neurotoxicity in two patients in
whom neurotoxicity was not anticipated due to normal albumin levels.
Case report
Case 1Introduction
Ifosfamide, an analog of cyclophosphamide, is an active agent in
gynecologic cancers, especially sarcomas (Dusenbery et al., 2005;
Kanjeekal et al., 2005). Its activity in ovarian and uterine malignant
mixed mesodermal tumors (MMMT) has been demonstrated in
multiple studies (Homesley et al., 2007; Mano et al., 2007;
Rutledge et al., 2006). Unfortunately, it is commonly associated
with neurotoxicity in patients with protein malnutrition. Its metab-
olism is primarily within hepatic enzymes (cytochrome p450) with
excretion through the urinary tract. Ifosfamide requires activation
through 4-hydroxyifosfamide to ifosforamide to exert cytotoxicity.
Deactivation of ifosfamide leads to the release of the potentially
neurotoxic chloracetaldehyde (Kerbusch et al., 2001).
Aprepitant is a novel and selective antiemetic that antagonizes
substance P/neurokinin 1 (NK1) receptors with high afﬁnity. Its
mechanism of action is distinct without cross-over from the com-
mon targets used to prevent chemotherapy-induced nausea and
vomiting: the serotonin (5-HT3), dopamine, and corticosteroidge of Medicine & Life Sciences,
e, Mail Stop 1194, Toledo, OH
r).
Inc. Open access under CC BY-NC-ND licensA sixty-seven year-oldwomanunderwent complete cytoreduction in-
cluding total abdominal hysterectomy, bilateral salpingo-oophorectomy,
bilateral pelvic and para-aortic lymphadenectomy, infragastric omen-
tectomy, splenectomy, and diaphragm tumor ablation for a stage
IIIc ovarian cancer. Final pathology revealed a homologous ovarian
MMMT.
The patient had Gynecologic Oncology Group (GOG) performance
status of one. Her pre-chemotherapy laboratory values were all within
normal limits including an albumin level of 3.5 g/dL (normal: 3.4–
5.4 g/dL). During cycles 1–3, the patient received cisplatin 20 mg/m2
along with ifosfamide 1.5 g/m2 daily over 90 min with concurrent
mesna on days 1–4. Her premedications included ondansetron 32 mg
and dexamethasone 10 mg. For four days after chemotherapy, she re-
ceived dexamethasone 8 mg every morning with metaclopramide
20 mg every 8 h, and ondansetron for refractory nausea and vomiting.
She had no neurologic toxicities with her ﬁrst 3 cycles but experienced
neutropenic fever as well as severe nausea and vomiting with her third
cycle. For her fourth cycle, her doses were adjusted as well as her
premedications and post-chemotherapy anti-emetics. For her fourth
cycle, she was to receive cisplatin 20 mg/m2 with ifosfamide 1 g/m2
daily over 90 min with concurrent mesna on days 1–4. His albumin at
this time was 3.6 g/dL, and her premedications included aprepitant
125 mg and dexamethasone 10 mg. Her post-chemotherapy regimen
was adjusted to add aprepitant 80 mg each morning along with dexa-
methasone 8 mg each morning for two days.
The patient still experienced nausea but had no emesis. After the
completion of her mesna on day 3 of chemotherapy, the patient
acutely developed an ifosfamide-induced coma without any precipi-
tating events. The ifosfamide infusion was discontinued. The coma
lasted less than 24 h and a methylene blue infusion was not used.
Supportive care and close monitoring in the step-down unit was
used. No residual neurologic toxicities were found. Interestingly, her
urinalysis revealed no red blood cells at any time.e.
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A forty-one year-old woman underwent a panniculectomy for
surgical exposure with total abdominal hysterectomy, bilateral
salpingo-oophorectomy, and peritoneal washings for complex endo-
metrial hyperplasia with atypia discovered by dilation and curettage.
Frozen section revealed a probable uterine MMMT. Therefore, she
underwent bilateral pelvic and para-aortic lymphadenectomy and
infracolic omentectomy. Final pathology revealed a homologous
uterine MMMT (stage IB).
The patient had GOG performance status of zero. Her pre-
chemotherapy laboratory values were all within normal limits, in-
cluding an albumin level of 4.5 g/dL. She was admitted for cycle
one of her chemotherapy the same day as the patient from Case 1
was admitted for cycle four. The plan was to give cisplatin 20 mg/m2
with ifosfamide 1.5 g/m2 over 90 min and concurrent mesna on days
1–4. Her pre-medications included aprepitant 125 mg and dexametha-
sone 10 mg. Her post-chemotherapy regimen consisted of aprepitant
80 mg each morning for two days along with dexamethasone 8 mg
each morning for the length of the chemotherapy (four days).
After her mesna and ifosfamide were completed on day 3 of
chemotherapy, the patient was noted to have developed acute
ifosfamide-induced mental status changes including—auditory and
visual hallucinations and labile emotions. The mental status changes
lasted less than 24 h and a methylene blue infusion was not used.
She also was closely monitored in a step-down unit. No residual neu-
rologic toxicities were found. Her urinalysis also revealed no red
blood cells at any time.
Discussion
MMMT's are a highly aggressive cancer often of uterine or ovarian
origin. Ideal chemotherapeutic management is still not known, howev-
er, three of the most commonly used agents are cisplatin, ifosfamide,
and paclitaxel.
Aprepitant is a moderate dose-dependent CYP3A4 inhibitor and in-
ducer of CYP2C9 (Anon, n.a.). It is currently recommended for use in pa-
tients receiving moderate to highly emetogenic regimens (Kris et al.,
2006). Aprepitant should not be used concurrently with several medi-
cines including but not limited to terfenadine, astemizole, and cisapride.
Dose-dependent inhibition of CYP3A4 may result in elevated plasma
concentrations of drugs metabolized through this system. While it
does affect the pharmokinetics of dexamethasone, it does not affect
the pharmokinetics of other chemotherapy agents (Loos et al., 2007).
Ifosfamide is metabolized by CYP3A4. Some of its metabolites can
cause neurotoxicity including: encephalopathy, sleepiness, dizziness,
hallucinations, coma and death (Ajithkumar et al., 2007). Ifosfamide
is administered as a racemic mixture of (R)- and (S)-ifosfamide enan-tiomers with the levorotatory enantiomer being responsible for the
neurotoxic side effects. Clinical case series have shown that the dura-
tion of neurotoxic side effects can be decreased by the administration
of intravenous methylene blue (Ajithkumar et al., 2007).
Malnutrition, as documented by decreased albumin, is one of
several factors that can inﬂuence the development of neurotoxicity
in patients receiving ifosfamide. Other factors include: the use of
cisplatin, high dose ifosfamide, prolonged infusion, rapid infusion,
or phenobarbital use. Both of the patients in this report had normal
albumin, but received concomitant cisplatin with their ifosfamide.
This combination of chemotherapies, although highly emetogenic,
may be better handled with steroids and 5HT3 antagonists as op-
posed to using aprepitant. Although it is easy to adjust the dose of
steroids used with aprepitant, it is much more difﬁcult to adjust
the dose of ifosfamide. Although some authors do not believe that
interactions with intravenous chemotherapies exist, we recommend
caution with the use of aprepitant in combination with ifosfamide
because of the potential for the development of acute neurotoxicity
until pharmacokinetic studies reveal appropriate dose adjustments
of ifosfamide with aprepitant.
Conﬂict of interest
None of the authors have any relevant conﬂicts of interest to report.
References
Ajithkumar, T., Parkinson, C., Shamshad, F., Murray, P., 2007. Ifosfamide encephalopathy.
Clin. Oncol. 19, 108–114.
Product information: Emend®, aprepitant, 2006. Merck & CO., Inc., Whitehouse Sta-
tion, NJ, USA.
Dusenbery, K.E., Potish, R.A., Argenta, P.A., Judson, P.L., 2005. On the apparent failure of
adjuvant pelvic radiotherapy to improve survival for women with uterine sarco-
mas conﬁned to the uterus. Am. J. Clin. Oncol. 28, 295–300.
Homesley, H.D., Filiaci, V., Markman, M., Bitterman, P., Eaton, L., Kilgore, L.C., Monk, B.J.,
Ueland, F.R., 2007. Gynecologic Oncology Group. Phase III trial of ifosfamide with
or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology
Group study. J. Clin. Oncol. 25, 526–531.
Kanjeekal, S., Chambers, A., Fung, M.F., Verma, S., 2005. Systemic therapy for advanced
uterine sarcoma: a systematic review of the literature. Gynecol. Oncol. 97, 624–637.
Kerbusch, T., Mathot, R.A., Keizer, H.J., Kaijser, G.P., Schellens, J.H., Beijnen, J.H., 2001.
Inﬂuence of dose and infusion duration on pharmacokinetics of ifosfamide and me-
tabolites. Drug Metab. Dispos. 29, 967–975.
Kris, M.G., Heskerth, P., Somerﬁeld, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M.,
Morrow, G.R., Chimnery, L.W., Chesney, M.J., Gralla, R.J., Grunberg, S.M., 2006.
American Society of Clinical Oncology guideline for antiemetics in oncology: up-
date 2006. J. Clin. Oncol. 24, 2932–2947.
Loos,W.J., deWit, R., Freedman, S.J., VanDyck, K., Gambale, J.J., Li, S.,Murphy,G.M., vanNoort,
C., de Bruijn, P., Verweij, J., 2007. Aprepitant when added to a standard antiemetic regi-
men consisting of ondansetron anddexamethasone does not affect vinorelbine pharma-
cokinetics in cancer patients. Cancer Chemo Pharmacol. 59, 407–412.
Mano, M.S., Rosa, D.D., Azambuja, E., Ismael, G., Braga, S., D'Hondt, V., Piccart, M.,
Awada, A., 2007. Current management of ovarian carcinosarcoma. Int. J. Gynecol.
Cancer 17, 316–324.
Rutledge, T.L., Gold, M.A., McMeekin, D.S., Huh,W.K., Powell, M.A., Lewin, S.N., Mutch,
D.G., Johnson, G.A., Walker, J.L., Mannel, R.S., 2006. Carcinosarcoma of the ovary—
a case series. Gynecol. Oncol. 100 (1), 128–132.
